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Reducing Benzodiazepine Use in the Treatment of Anxiety in a Community Mental Health
Setting
Background and Significance
Anxiety disorders are among the most common mental health disorders in the United
States according to the Substance Abuse and Mental Health Administration Services
(SAMHSA), affecting nearly 18% of the adult population annually (SAMHSA, 2013).
Modalities for the treatment of anxiety disorders shifted in the late 1980s and early 1990s
because of concerns in the medical community regarding the risks of abuse and dependence
engendered by the long-term use of benzodiazepines (Smith & Tett, 2010). The most common
treatment approaches have included a combination of non-pharmacological interventions and
medication approaches as endorsed in the United Kingdom in the seminal work of Dr. C.
Heather Ashton (Ashton, 1994) and mirrored by the American Psychiatric Association in its own
seminal work in the United States (APA, 1990.)
A consensus report was adopted by the American Psychiatric Association (APA) to limit
the use of these agents and best practice models were adapted to guide prescribers (APA, 1990).
These best practices included limiting benzodiazepines to short-term use due to their risk of
tolerance and dependence (NICE, 2011). The use of benzodiazepines, according to a best
practices model, should be limited to crisis intervention or to assist in the abatement of the most
severe anxiety and panic symptoms, with the intent to concurrently prepare the patient for the
work of learning to manage anxiety and panic (Ashton, 1994).
It is an accepted tenet that the extended use of these agents to treat anxiety encourages
abuse and dependence and compromises the sobriety of individuals recovering from alcohol and

illicit drug dependencies (APA, 1990; Ashton, 1994). Additional risks inherent in the use of
benzodiazepines occur when the drug is abruptly withdrawn or not available to an individual
who has developed dependence include seizure activity, withdrawal symptoms, rebound anxiety
and rebound hypertension (APA, 1990, p. 35). Recent research has also implicated the use of
benzodiazepines in increased incidences of dementia (de Gage, et al. 2012).
Benzodiazepines continue to be prescribed often: 112.8 million benzodiazepine
prescriptions were filled in 2007 (Cascade & Kaskali,, 2008). Data from 1987 indicates that this
number was 10.9 million (Olfson & Pincus, 1994). According to the Centers for Disease Control
(CDC) death rates attributable to overdoses more than tripled since 1990 (CDC, 2011). While
prescription pain medications, primarily opiates, are responsible for three out of four prescription
drug-related deaths, over half of those deaths involve concomitant use of benzodiazepines,
cocaine and alcohol (CDC, 2011). The American Academy of Pain Medicine (AAPM) recently
released a report based on CDC data indicating that 30% of prescription drug deaths result from
an opioid-benzodiazepine combination (AAPM, 2013). The study by Bachuber, et al. (2016)
noted that overdose deaths from benzodiazepines increased from .58 per 100,000 in 1996 to 3.07
per 100,000 in 2013.
For the past twenty years, the standard of care for the treatment of anxiety
disorders has consisted of psychotherapeutic modalities: cognitive-behavioral therapy (CBT,)
mindfulness and relaxation techniques, as well as other non-medication-focused treatments. The
first-line approach, during this same time span, has also consisted of medications that target
neurotransmitters believed to play major roles in the mediation of symptoms associated with
anxiety disorders; these medications have included Selective Serotonin Re-uptake Inhibitors

(SSRIs,) Serotonin and norepinephrine re-uptake inhibitors (SNRIs,) GABAergic agents and
other non-benzodiazepine anxiolytics.
In spite of this standard of practice (Magellan, 2012), the use of benzodiazepines has not
significantly decreased. A recent study conducted by Bachhuber, Hennesey, Cunningham, and
Starrels (2016), using data from the CDC, concluded that between 1996 and 2013, the number of
filled prescriptions for benzodiazepines, in the adult population, rose from 4.1% to 5.6%. If
actual practice deviates from established standards of practice, as the data supports, (Sanyal,
Asbridge, Kisely, Sketris & Andreou, 2011), the reasons for this deviation must be explored and
an attempt made to determine if there is a valid reason to alter the best practices approach.
Conversely, if this deviation from care continues to exact the price of poor outcomes and
abuse/dependence that has previously been established, practitioners must be encouraged to
conform to these best practices.
Purpose
The purpose of this project is to develop and implement an evidence based pilot program
that uses an internet-based, cognitive-behavioral program to successfully wean clients using
benzodiazepines for anxiety disorders with minimal to no perceived participant distress and to
reduce the risk of dependence, addiction, and overdose with these agents.
Literature Review
An initial search was conducted using the standard CINAHL nursing database. This
initial search netted few germane research articles. Therefore, the search was broadened to
include the following journal databases: Academic Search Premier; CINAHL, Health and
Psychosocial Instruments, Health Source - Consumer Edition, Health Source: Nursing/Academic

Edition, MEDLINE, PsycARTICLES, Psychology and Behavioral Sciences Collection and
PsycINFO. The Substance Abuse and Mental Health Services (SAMHSA) website was also
searched for relevant scholarly articles, and resources.
Because the topic of interest included best practices models and practice guidelines, the
following web-sites were also searched: National Institute of Health (NIH), National Institute of
Mental Health (NIMH), American Psychiatric Nurses Association (APNA) policy papers,
American Medical Association (AMA) policy papers, Kentucky Board of Nursing (KBN), and
the National Guideline Clearinghouse.
Throughout the search, several search terms were used. Initially, basic terms such as
“anxiety disorders”, “benzodiazepines”, “treatment of anxiety” were used. It was quickly
apparent that these search terms were often too vague or too broad to garner relevant research
studies. Therefore, numerous journal articles were reviewed and other terminology was used to
refine the previous searches. Effective search terms included: “treatment of anxiety disorders in
PTSD”, “cognitive-behavioral therapy”, and “mindfulness” among many others. The initial
literature search was halted when saturation was reached.
Thirty-eight articles were determined to be relevant to this review. Of those articles,
twelve contained randomized-controlled trials (RCTs). Of the studies that included RCTs, nine
of those were integrated studies, consisting of quantitative and qualitative data. Because of the
subjective nature of outcomes most commonly measured in psychiatric research, integrated
studies often capture data that is difficult to quantify. Four of the studies included were
descriptive studies and six were systematic literature reviews. Three articles meeting criteria for
inclusion in this review were clinical guidelines. Also included in this review were two focus

groups study, an expert opinion paper, four post-hoc integrated studies, one criterion-standard
study, and five descriptive studies.
The seminal work from the APA (1990) identified the inherent problems of addiction and
dependence with long-term benzodiazepines and recommended that physicians alter their
practices to consider the use of talk therapies as first-line modalities of care for the treatment of
anxiety. It declines to make specific recommendations for time limits on the prescribing of
benzodiazepines, possibly due to its reluctance to hinder the judgment of the individual
physician’s judgment. There are no follow-up publications or white papers by the APA that have
addressed this practice standard since the 1990 publication. Another seminal work, this time
from Great Britain, The Ashton Report (Ashton, 1994) set forth similar practice guidelines for
psychiatrists, urging limited use of benzodiazepines and encouraging providers to employ more
talk therapies as first-line courses of treatment for anxiety. Magellan (2012) published clinical
guidelines promoting talk therapies such as CBT as the first line of treatment for individuals with
anxiety disorders. It recommends talk therapies plus medications as first line treatments, but
specifically attempts to dissuade providers from including long-term benzodiazepines within the
definitions of first line medications.
Gosselin, Morin, Dugas, & Baillargeon (2006) demonstrated the positive benefits of CBT
in their Canadian study. These researchers gathered a convenience sample, later randomized to
groups, through media ads. The initial respondents (N=273) were screened for study inclusion.
The criteria for study inclusion was based on individuals meeting the criteria for Generalized
Anxiety Disorder, currently prescribed a benzodiazepine and expressing a willingness to
discontinue treatment with those agents (N= 61). These participants were randomized to two
groups: one group received usual care (n= 30) and the other group received CBT (n= 31). At the

end of the three month study, 74% of the group who received CBT had discontinued
benzodiazepines versus 36% in the group receiving usual care. These findings supported the
hypothesis that the addition of CBT to treatment for people with anxiety can increase the ability
to wean them from these agents. Follow up anxiety screening using the Worry and Anxiety
Questionnaire demonstrated continued benefits of CBT at the 6- and 12-month assessment
points.
In an effort to locate existing research on current policy, laws, and statistical information
related to the prescribing of controlled substances, specifically benzodiazepines, a literature
search was pursued using Google Scholar, Google, and National Institute for Mental Health
(NIMH) databases. This search netted sixteen germane articles. Of these sixteen articles, two
were time series analyses of prescribing habits (Cunningham, Hanley, & Morgan, 2010;
Dormuth, Miller, Huang, Mamdani., & Juurlink, 2012).One study was a prospective analysis.
The remaining thirteen articles were white papers, statistical reports and laws pertaining to the
prescribing of controlled substances in the United States, Great Britain, Ireland, Canada and
Australia. Practice guidelines and statistical data from the World Health Organization (WHO)
were also obtained.
Figures released by the Kentucky Injury Prevention and Research Center (2014) report
that the number of overdose-related hospitalizations involving benzodiazepines in Kentucky in
2000 was 793; in 2013 that number was 1,686 (Svetla, Bunn, & Lambert, 2014). The cost of care
for all drug overdose hospitalizations (of which benzodiazepines are the singular cause or
contributory) rose from $21.1 million in 2000 to $129.3 million in 2012; total days of
hospitalization days for overdoses in Kentucky rose from 10,385 in 2000 to 21,344 in 2012
(Svetla et al., 2014). The 2013 report issued by Trust for America's Health (TFAH) found that

Kentucky ranks third in the nation in drug overdose mortality and that a large proportion of
those deaths are prescription drug related (TFAH, 2013). The same report, however, endorsed
Kentucky as one of the leading states in its corrective planning to curb those deaths, including
increased education for prescribers, increased real-time access to a controlled drug monitoring
program and efforts to educate the public on the dangers of misuse of prescription drugs (Trust
for America's Health, 2013).
In response to increasing deaths associated with prescription drug overdoses, primarily
opiates but also benzodiazepine-only or combination overdoses that include benzodiazepines, the
Kentucky Legislature adopted House Bill 1 (now KRS 218A) to hold prescribers more
accountable for the prescribing of the agents (as well as psychostimulants) in 2013. Its purpose
was to outline the requirements of prescribers to provide minimal assessment, documentation of
need, review of the state’s controlled reporting system [KASPER] and engaging in education
with clients that is documented by written contracts between the patient and the prescriber,
signifying the patient is aware of the conditions under which these controlled agents would be
prescribed (Cohron, 2014; Parton, 2012).
Theoretical Framework
The recovery model provides the theoretical underpinning of this project (Anthony,
1993). The recovery model developed out of the “survivor” movement of the 1970s when a
number of people with mental illnesses began to write about their experiences with
institutionalized (whether inpatient or community) psychiatric care. These pioneers considered
themselves survivors and ex-patients as they pulled away from traditional, pharmacological, and
restrictive treatments. Initially, there was much opposition between these consumers and the

professionals who considered their labors to be minimized at best and vilified at the worst. Over
the ensuing decades, these sides have come together in a less oppositional manner and have, over
time, contributed to a body of knowledge that has formalized the recovery model as a conceptual
framework.
The core belief of the recovery model is that people get better. Their illness is a reality
and has changed their lives, forever. People move on and the illness does not have to remain a
focus of their entire lives (Anthony, 1993). It is not a necessary result of mental illness to lose all
the roles that people have achieved or strive to achieve. Recovery can concretely be interpreted
as recovering valued roles: worker, student, parent, significant other, sibling, author, and so on.
Any dreams that a person without a mental illness is entitled to, so is a person with a mental
illness. As a result of the “take back our lives” focus of the originators of the recovery model,
stakeholders in mental health (providers and consumers alike) have adopted a person-centered,
respectful stance with those individuals who must deal with a mental illness that impacts all
areas of their lives. A basic tenet of the recovery model is responsibility for self: “The recovery
model emphasizes that responsibility for and control of the recovery process must be given in
large part to the person who has the condition.” (Frese, Stanley, Kress & Vogel-Scibilia, 2001).
Mental health providers have gradually come to incorporate this model and its philosophy into
day-to-day care, treatment planning and goal-setting.
Best practices treatment for anxiety, such as cognitive-behavioral therapy, are consistent
with the recovery model. In CBT, the person is taught the tools to rethink, reframe and thus
change their own behaviors in coping with anxiety- provoking thoughts and circumstances. Once
taught, these tools cannot be un-taught and remain lifelong skills for the person. Conversely, the
use of benzodiazepines inherently requires a consistent dependence on a prescriber so that the

prescriber can provide the “tool” to decrease anxiety in the form of a pill; and with
benzodiazepines, the “choice” is much reduced for the consumer by the very nature of their
mechanisms of action.
Methods and Procedures
Design. This was an evidence-based pilot project using a one-group, pre-test, post-test
model.
Setting. This pilot project was conducted in an urban community mental health center in
the southeastern United States that serves over 1,900 clients. This center serves adults with a full
complement of mental illnesses, intellectual disabilities, substance use disorders, and other
emotional and behavioral disturbances.
Population. The project coordinator (DNP student) identified three colleagues who
voiced a willingness to participate in the recruitment of participants from their caseload of
patients currently receiving benzodiazepines. A search was conducted using the agency’s
electronic prescribing software to obtain a list of active prescriptions for benzodiazepines
prescribed by the three colleagues as well as the project coordinator. This resulted in a list of
over 60 people. From that list, only individuals who met the criteria for the project were
included. Excluded individuals were those with developmental disabilities, traumatic brain
injuries and dementia. The rationale for this exclusion is the presumption that there may be
limited ability on the part of these individuals to successfully access and retain the information
available in the web-based CBT program. The resulting number of potential participants was 38.
All potential participants were invited into the project by the project coordinator, either in
person or through a letter of invitation sent in advance of their next scheduled appointment with

their respective prescriber. In the letter, a brief introduction of information was made regarding
the intended project and an invitation to discuss this opportunity with his or her prescriber at the
next visit with the prescriber. The prescribers were asked by the project coordinator to follow up
with these clients at their next scheduled visit to discuss the project further and to engage the
project coordinator for further instruction if the patient evidenced any interest in engaging in the
project.
The time period for enrolling participants in the pilot project was from January 1, 2016 to
March 31, 2016. At the end of the enrollment period, the total number of patients who were
willing to participate was seven. All participants were clients of the project coordinator. While
the other involved prescribers informally informed the project coordinator that he or she had
heard affirmative responses from “some’ of their patients none, ultimately, agreed to engage in
the pilot.
Sample. This was a convenience sample of seven clients. All were over 18 years old and
had been prescribed long-term benzodiazepines. For the purposes of this project, long-term was
defined as greater than four months.
Data Collection. Data was collected documenting the dosages of prescribed
benzodiazepines for each participant at the beginning and end of this project to assess any
decrease in usage. Data was collected to reflect if each participant used the web-based program
during the project. Data was collected in the form of pre-project levels of anxiety using the
GAD-7 at the beginning of participation in the project and at the end of participation.
Additionally, the use of individual or group therapy was controlled for by collecting data
regarding each participant’s pre-project participation in therapy and any participation in therapy

during the project and any differences were noted. Demographic data was gathered for
participants and non-participants in the project for further analysis post-project.
Instrument. The Generalized Anxiety Disorder scale-7, GAD-7, (Appendix A) was used
as the measurement tool to assess levels of anxiety in participants. The GAD-7 was developed in
the mid-1990s as a brief screening tool for self-assessment of anxiety symptoms. It has been in
common use in behavioral health services since and has been used extensively in clinical practice
as well as for study purposes (Kroenke, Spitzer, Williams & Lowe, 2007). In one large-scale
study, the originators of the GAD-7 tested the instrument within a population of greater than
2700 patients. This study determined that the GAD-7 was an efficient and effective screening
tool with a specificity of 82% and a sensitivity of 89% and was determined to have good
reliability and procedural validity (Spitzer, Kroenke, Williams & Löwe, 2006).
Intervention. In an effort to minimize the risk of increased anxiety during this project, all
participants were given written and verbal information to engage in a self-help web-based CBT
program entitled “Living Life to the Full. (Appendix B.) This web-based program was developed
by Dr. Chris Williams, a psychiatrist at the University of Glasgow. Each participant was also
offered on-site access to a computer and one-on-one assistance to activate the program for their
use.
Procedure. At entry into the project, each participant’s daily dosage of benzodiazepine
was recorded by the project coordinator. Each patient was administered the GAD-7 at the entry
into the project to assess baseline anxiety. Each patient was provided with the verbal and written
directions to access the web-based, self-help program based on cognitive-behavioral concepts
(“Living Life to the Full.”). Each patient’s benzodiazepine dose was reduced by no more than

one-half pill within their dosage range of every month until the project was completed (i.e., if the
patient’s current regimen was 1 mg of clonazepam twice daily, the dosage was reduced to 0.5 mg
in the morning and 1mg in the evening for a month at least, then reduced to 0.5 mg twice daily
for a month, and so on.). At every med check, the prescriber monitored the client’s subjective
experience and if the client was actively participating on her/his own in the web-based program.
At each med check the prescriber encouraged the use of web-based participation, offered support
and any needed additional assistance (i.e. help via Peer Support Specialists, therapists, case
managers). Once each participant’s involvement in the project concluded, the GAD-7 was
administered and pre- and post-project results were compared.
Stakeholders
There were numerous stakeholders involved in this project. The implementation of this
project had a direct impact on prescribers’ practice; each was asked to enroll clients who met
inclusion criteria. The time involved in adding this component to the prescribers’ already-full
routine to reach potential participants was not inconsiderable. Additionally, time within
scheduled sessions was needed to allow the prescribers to explain the risks of long-term
benzodiazepine use and the process of weaning and its implications. Another stakeholder in this
process was the patient. He or she was asked to consider alternate therapies for the treatment of
anxiety symptoms, not just benzodiazepines. The changes asked of the client impacted time in
session, it challenged the way the client regarded benzodiazepine dependence on his/her life, and
the potentially decreased amount of time spent, overall, dealing with the mental health system
having discarded the dependence on prescribers’ discretionary provision of benzodiazepines.

Therapists, case managers and peer support specialists comprise another portion of
stakeholders in that they were asked to assist clients in addressing their anxiety via the use of the
CBT program. While none of the eventual participants engaged in the offered CBT program,
these clinicians were still asked to take the time to be prepared for the possibility The business
staff had a stake in this project in that there were variations in their time spent assisting clients in
accessing benzodiazepine prescriptions and trouble-shooting problems with these agents.
Insurance companies and other third-party payers have a stake in this project in that they
provide the means by which clients afford this care. A change in treatment that is less prescriberdependent and allows for self-help by the patient potentially reduces the cost of health care.
Families and support networks comprise another portion of the stakeholders for this project;
more effective symptom treatment for the patient (their significant other) may convey limited
burden to these individuals as well. A final stakeholder is the community mental health center
(CMHC) itself. Reducing prescriber-dependent treatment by the implementation of a web-based,
self-help program may reduce the number of visits to prescribers and thus reduce reimbursement.
Conversely, for over-burdened CMHCs, this could translate into more available time for other
clients with more complex and more severe mental illnesses. The CMHC may also need to
change some of its policies and procedures to align with best practices in the treatment of clients
with anxiety symptoms.
Responsibilities of the Team
Project coordinator (DNP Student): Designed and implemented the project; shared with
other prescribers a project overview, its goals, any time limits, the intervention (web-based CBT
program)—attempted to ensuring access/buy-in to program, ongoing encouragement to use

web-based program themselves and with clients. Administered GAD-7 to participants at
beginning and end of project participation, collected data, served as “problem-solver” throughout
project, interpreted data, ensured confidentiality and enrolled participants.
Peer Support Specialists: Remained available to assist clients in accessing computer, if
needed, via on-site computer lab. They also were available to assist clients with any learning
needs to ensure adequate understanding and utilization of web-site.
Therapists and Case Managers: They were made aware of clients that were in the process
of tapering from benzodiazepines and provided additional support as needed to those clients.
Business Staff: Assisted in the monitoring of benzodiazepine use by accessing
KASPER/INSPECT/electronic prescribing programs and forwarded this info to the project
coordinator (DNP student) for data collection when requested.
Data Collection Plan and Tools
This project used two author-produced data collection. The Project Demographics chart
for participants (Appendix C) was used to gather demographic data on all active participants in
the project as well documentation of benzodiazepine dosage, pre- and post-project, use of the
CBT web-based program and GAD-7 scores, pre- and post-project. The second tool used was the
Project Demographics for non-participants (Appendix D) which gathered demographic data for
those individuals opting out of the project. At the end of the project, all data from individual
demographic forms was compiled through the use of the Aggregate Data- Participants form
(Appendix E).

Evaluation Plan
Short-term goals:
1. All participants will successfully reduce or discontinue use of benzodiazepines by the end of
the pilot project. “Successful” reduction is defined as greater than fifty percent of pre-pilot
dosage.
2. All participants will demonstrate an acceptable level of distress while reducing
benzodiazepine dosages throughout this pilot project as evidenced by less than a 4 point increase
in GAD-7 scores from baseline scores.
3. At least 75% of participants will report participation in the web-based program by the end of
the project.
Long-term Goal:
The pilot project will be converted to usual practice standards within the entire CMHC by
the end of one year, bringing the agency into compliance with established best practices for the
treatment of anxiety symptoms.
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Evaluation
Outcome
Indicator

Measure/Operational
Definition

Participants will
successfully
reduce their
daily dose of
benzodiazepines
by the end of
the pilot project
(2 months.)

“Significant
reduction” is defined
as >50% reduction
from pre-pilot daily
dosage to end of
pilot/dosage.

(Short-term
goal)

Participants will
report minimal
increase in
anxiety by end
of pilot project.

“Minimal increase in
anxiety” is defined
as less than a 4 point
increase in GAD-7
scores.

Rationale for
Measure
Selection
Gradual
tapering (dose
reduction) is
preferred to
abrupt
withdrawal of
benzodiazepines
to reduce risk of
withdrawal
seizures,
rebound
symptoms,
rebound
hypertension
and
psychological
distress
(APA, 1990, p.
35)

A 4-point
delineation in
scoring on the
GAD-7 may
indicate a
clinically
significant

Data Collection
Approach

Benchmark

Improvement Goal

Upon entry and No established
completion of
benchmarks
the pilot
program
participants’
daily doses of
benzodiazepines
were collected
from patient
charts,
electronic
prescribing
program and
KASPER
reports and
documented on
Project
Demographics
for Participants
form.

25% decrease in
overall prescribing of
benzodiazepines
within first 6 months
of agency
implementation:
Number of clients
prescribed
benzodiazepines at
end of 6 months
following
implementation/
number of clients
prescribed
benzodiazepines at
beginning of 6 month
implementation

Baseline GAD7 scores will be
obtained for
each participant
prior to
beginning the
weaning

Less than 4 point
increase in GAD
scores in clients with
anxiety within the first
6 months of
implementation within
the agency

No established
benchmarks
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(Short-term
goal)

The use of a
web-based CBT
program
(“Living Life to
the Full”) will
minimize
increased
anxiety
symptoms.

(Short-term
goal)

change in
distress—On
the GAD
scoring scale,
changes in
severity of
anxiety
symptoms are
grouped into 4point variations.

At least 75% of
participants will
report active use—
defined by accessing
an individual
account on web-site
(“Living Life to the
Full”) at some point
during the pilot
project.

process; these
scores will be
documented on
Project
Demographics
for Participants
form.
GAD-7 Scores
will be obtained
on each
participant at
(Spitzer,
the conclusion
Kroenke,
of pilot project
Williams, &
and documented
Löwe, 2006.)
on the Project
Demographics
for Participants
form.
CBT has
Patient use of
No established
consistently
web-based
benchmarks
been shown to
program will be
decrease anxiety documented in
symptoms in
the patient
numerous
record and
diagnostic
collected by
categoriesproject
Generalized
coordinator
Anxiety
(DNP student)
Disorder, Panic and recorded on
Disorder,
Project
PTSD, etc.
Demographics
(Linden,
for Participants
Zubragel, &
form.

18

25% of agency-wide
client population will
access web-based CBT
program within first 6
months of
implementation
agency-wide
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Bar, 2011;
Andrews,
Davies, &
Titov, 2011;
Hendriks, Oude
Voshaar,
Keijsers,
Hoogduin, &
van Balkom,,
2008; Khoo,
Dent, & Oei,
2011).
Internet-based,
self-help CBT
programs have
been shown to
be as
efficacious in
the reduction of
anxiety
symptoms as
face-to-face
CBT therapy.
(Andrews,
Davies, &
Titov, 2011;
Titov, Andrews,
Schwencke,
Robinson,
Peters, &
Spence, 2010).
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Process
Indicator
Education/reeducation of all
clinicians to
accurately
administer
GAD-7

Measure/Operationa
l Definition
Accuracy will be
measured by selfreport and
demonstration to
project coordinator
(DNP student)

Rationale for
Measure Selection
The
questionnaires rely
on patient selfreport, all
responses should
be verified by the
clinician and a
definitive diagnosis
made on clinical
grounds, taking
into account how
well the patient
understood
the questionnaire,
as well as other
relevant
information from
the patient.

Data Collection
Benchmark
Approach
Project
No established
coordinator
benchmarks
(DNP student)
will be
responsible for
individual
instruction and
“check-off” of
proficiency
with each
clinician.

Improvement Goal

GAD-7 is the tool
selected to measure
anxiety symptoms
and distress to guide
clinical practice
during weaning
process.

Withdrawal
symptoms during a
benzodiazepine
weaning program
consist primarily of
increased anxiety
(Ashton, 1994).

GAD-7 scores
will be
documented in
the patient
record by the
prescriber and
data will be
collected using
Project
Demographics
for Participants
form.

80% in administering
GAD-7 at baseline and
at completion of pilot
project, allowing for
participant attrition.

(Short-term
goal)

Prescribers will
obtain baseline
GAD-7 and
GAD-7 at the
completion of
the project
(Short-term
goal)

20

No established
benchmarks

All clinical staff will
demonstrate
competency in
administering GAD-7
by start of agency-wide
implementation
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Clinicians will
be responsible
for ensuring
each participant
has access to
and knowledge
of web-based
CBT program
(“Living Life to
the Full”)
Project
coordinator
(DNP student)
will be
responsible for
eliminating
access barriers
by providing
access to
computer and
individual
instruction if
needed.
(Short-term
goal)

Access is defined as
having a personal
computer or handheld device that can
access the internet.
“Knowledge of” is
defined as working
understanding of
how the web-site
works as evidenced
by a return
demonstration by
the participant
For clients who do
not have access,
computers and
computer lab will be
made available onsite.
Additional support
will be available via
use of Peer Support
Specialists to ensure
adequate comfort
level in accessing
web.

Familiarity and
adequate comfort
levels in the
utilization of webbased treatment
programs reduces
attrition
[Price, Gros,
McCauley, Gros, &
Ruggiero, 2012).

Clinicians will No established
document in the benchmarks
patient record
any and all
instruction,
reinforcement
of web-based
program and
identify any
barriers to
access for the
individual
participant.
Project
coordinator
(DNP student)
will be
responsible for
eliminating
access barriers
by providing
access to
computer and
individual
instruction if
needed.
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50% of target clients
verbalize understanding
of web-based program
and access to the
program

REDUCING BENZODIAZEPINE USE IN TREATING ANXIETY
Prescribers will
follow a
consistent
weaning
protocol.

(Short-term
goal)

Weaning protocol is
defined as a
reduction no more
than 0.5m/day per
month for each
participant.

Gradual tapering
(dose reduction) is
preferred to abrupt
withdrawal of
benzodiazepines to
reduce risk of
withdrawal
seizures, rebound
symptoms, rebound
hypertension and
psychological
distress
(APA, 1990, p. 35)

Dose
No established
reductions and benchmarks
the rationale for
same will be
documented in
the patient
record.
Project
coordinator will
be responsible
for collecting
this data via
patient records,
e-prescribing
software and
KASPER
reports and that
data will be
documented on
Project
Demographics
for Participants
form.
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100% compliance with
no more than
0.5mg/day dose
reduction per month
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Expenses
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Demographics
Non-participants
Age
18-24 years
25-34 years
35-44 years
45-54 years
55-64 years
65-74 years

3%
16%
16%
45%
3%
16%

Gender
Male
Female

33%
67%

Marital Status
Single, Never Married
Married
Living with Partner
Widowed
Divorced
Separated

26%
15%
10%
3%
39%
3%

Ethnicity
Caucasian/White
African American/Black
Native American/American Indian
Asian/Pacific Islander
Other

58%
19%
0
0
23%

Educational Level
None
K-8
Some High School/No Diploma
High School graduate/GED
Some College/No Degree
Bachelor’s
Master’s

0
3%
26%
39%
32%
.03%
0
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Employment Status
Not Working/Looking
Not Working/Not Looking
Part-time
Full-time
>1 job

6%
81%
6%
6%
0

Student
No
Part-time
Full-time

94%
0
6%

Diagnoses
Major Depression
Other Anxiety Disorders
Post-Traumatic Stress Disorder
Bipolar I Disorder
Attention Deficit Disorders
Generalized Anxiety Disorder
Panic Disorder
Obsessive-Compulsive Disorder
Bipolar II Disorder
Schizophrenia
Alcohol Use Disorders
Traumatic Brain Injury
Intellectual Disabilities
Mood Disorder NOS
Autism Spectrum Disorders
Intermittent Explosive Disorder
Anxiolytic Dependence
Schizoaffective Disorder
Borderline Personality Disorder

Participants
Age
18-24 years
25-34 years
35-44 years
45-54 years

0
0
14%
29%

44%
22%
19%
16%
15%
15%
12%
1%
1%
1%
1%
.03%
.03%
.03%
.03%
.03%
.03%
.03%
.03%
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55-64 years
65-74 years
> 75

43%
0
14%

Gender
Male
Female

29%
71%

Marital Status
Single, Never Married
Married
Living with Partner
Widowed
Divorced
Separated

29%
29%
0
13%
29%
0

Ethnicity
Caucasian/White
African American/Black
Native American/American Indian
Asian/Pacific Islander
Other

86%
14%
0
0
0

Educational Level
None
K-8
Some High School/No Diploma
High School graduate/GED
Some College/No Degree
Bachelor’s
Master’s

0
0
29%
43%
29%
0
0

Employment Status
Not Working/Looking
Not Working/Not Looking
Part-time
Full-time
>1 job

0
86%
14%
0
0
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Student
No
Part-time
Full-time

100%
0
0

Diagnoses
Post-Traumatic Stress Disorder
Generalized Anxiety Disorder
Major Depression
Borderline Personality Disorder
Attention Deficit Disorders
Bipolar I Disorder

51%
43%
29%
29%
14%
14%
Results

1) Goal: All participants will successfully reduce or discontinue use of benzodiazepines by the
end of the pilot project. A “significant” reduction is deemed, by the project coordinator, to be
at least 50%.
Participant Beginning Benzo Dosage
01
3mg/day
(lorazepam)
02
1mg/day
(clonazepam)
03
1mg/day
(clonazepam)
04
5mg/day
(diazepam)
05
2.5mg/day
(clonazepam)
06
1mg/day
(clonazepam)
07
1mg/day
(clonazepam)

Ending Benzo Dosage
2mg/day
(lorazepam)
0mg/day
(clonazepam)
.75mg/day
(clonazepam)
0mg/day
(diazepam)
1.5mg/day
(clonazepam)
,5mg/day
(clonazepam)
0mg/day
(clonazepam)

% Decreased
33%
100%
25%
100%
60%
50%
100%
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Result: Four out of seven participants (57%) reduced their daily benzodiazepine dosage by 50%
by the end of the project. All reduced their dosages in a range of 25-100%; the total average for
the sample was 66%. Of note: all but one of these participants were taking clonazepam or
diazepam, both agents have relatively long half-lives, especially diazepam. Patients, who engage
in a tapering program on an agent such as alprazolam, may be especially prone to subjective
withdrawal symptoms or rebound anxiety due the short half-life of that particular agent.
2) Goal: All participants will demonstrate an acceptable level of distress while reducing
benzodiazepine dosages throughout this pilot project as evidenced by less than a 4 point
increase in GAD-7 scores from baseline scores.
Participant

01
02
03
04
05
06
07

GAD-7 at
Beginning of
project
17
16
19
13
21
7
19

Ranking of
Score per
GAD-7
Severe
Severe
Severe
Moderate
Severe
Mild
Severe

GAD-7 at
End of
project
8
16
21
11
8
8
18

Ranking of
Score per
GAD-7
Mild
Severe
Severe
Moderate
Mild
Mild
Severe

Increase/Decrease/No
Change
Decrease
No Change
No Change
No Change
Decrease
No Change
No Change

Result: All demonstrated an acceptable level of distress by the end of the project. Five out of the
seven (71%) demonstrated no changes in their GAD-7 scores and 2 out of the seven (28%)
showed a decrease in GAD-7 scores.
3) Goal: At least 75% of participants will report participation in the web-based program by the
end of the pilot project.
Result: None of the participants used the web-based CBT program.
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Control:
The project controlled for therapy.
Participant
01
02
03
04
05
06
07

In Therapy at Beginning
of project?
Y
Y
Y
N
N
N
Y

In Therapy at End of
project?
Y
Y
Y
N
N
N
N

Change in Frequency of
sessions?
N
N
N
n/a
n/a
n/a
Y-stopped therapy

There were no changes in active therapy status for 6 of the 7 (85%) participants. One
participant stopped therapy during the project. (Of note is that that participant’s GAD-7 score did
not change from pre- to post- project levels.)
As of August 2016, all participants in this project have remained active clients of the
agency. All but one have completed their tapering programs successfully. The one remaining
client is now on .5 mg clonazepam at bedtime with a goal to stop that dose at her next prescriber
appointment. None of the participants have gone outside the agency for additional
benzodiazepines, as evidenced by KASPER reports.
Barriers and Solutions
One anticipated barrier was a potential for lack of competency and/or comfort on the
patient’s part to engage in a web-based CBT program. Therefore, staff was available for
rudimentary instruction and guidance in assuring that clients felt sufficiently competent in
accessing the web-site. In this small sample population, no one used this tool so the resource was
not needed, but for future implementation of these best practices, access to staff that is
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knowledgeable and competent to assist clients with the tool as well as other CBT tools would be
invaluable.
Another anticipated barrier was the reluctance of the patient to allow a reduction in
benzodiazepines. While involvement in this project was voluntary, the onus was on the
prescriber to provide education regarding the benefits of non-benzodiazepine treatment. Clients
taking benzodiazepines are historically very reluctant to consider other forms of treatment and
anticipatory anxiety increases when confronted with the possibility of “losing” the
benzodiazepine.
Resistance on the part of the prescriber could have been, and likely was, in this project, a
barrier. Implementing change requires varying degrees of commitment both in terms of beliefs as
well as a willingness to commit the time it takes to implement change, a willingness to consider
change and a buy-in to the underlying belief that what one is doing is truly best. This may or may
not have been a contributor to the absence of participants in the project other than the project
coordinator’s clients.
Not all the prescribers who expressed interest in this project and a willingness to
participate work in the same setting. Thus their proximity to the project coordinator was limited.
Even if a patient invited into the project voiced some interest, these prescribers did not have
immediate access to the project coordinator to enlist that patient’s active involvement. Nor did
the prescribers have the benefit of proximity to simply share in the day-to-day recruitment,
sharing of knowledge and resources in order to enlist more active participants.
Ethical considerations. As the only participants into this project came from the Project
Coordinator’s caseload, it was incumbent on this prescriber to avoid coercion. Only clients for
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whom this project coordinator was already tapering benzodiazepines were even invited into the
project. Since the project coordinator had the “power” over prescribing these agents, it was
deemed unethical to ask any client into the project who had not already consented to a tapering
program months prior to the start of this pilot project.
Unintended Consequences
The project coordinator anticipated that the participants would need some intervention
added to their modalities of care to lessen the risk of increased anxiety, but none of the
participants engaged in this program. In spite of that, there were no increases in overall anxiety.
While the addition of another tool to manage anxiety during a tapering process may indeed be
helpful, the lack of use of this program did not appear to impact these specific individuals.
One patient left treatment altogether subsequent to this tapering program. It is not clear if
this medication change impacted that person’s decision to leave treatment as she simply dropped
from care.
The use of the letter to invite clients into the project appears to have increased one
person’s paranoia. The letter, sent to a client not under the care of the project coordinator,
prompted him to bring the letter to discuss with his prescriber asking how and to whom his
medical records had been released. When she explained that his name had been provided by her
as an invitation to participate in the project, he actually verbalized an initial interest but later
withdrew his name from consideration, offering no reason. So, in future studies, greater care
should probably be taken to alert clients that they may be invited into a project before they are
even approached.
Recommendations
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It is recommended that the agency engage in an ongoing practice of educating
prescribers, clinicians and clients in the best practices approach to the treatment of anxiety and
work diligently to limit the use of benzodiazepines, if at all, to less than a few months as
recommended by the literature. This project demonstrates, in a small way, that the perceived risk
of an increase in anxiety once these agents are reduced and/or eliminated may not necessarily
have a basis in fact or real experience.
Group support has long been a staple of mental health services. The agency should
consider developing groups for people with anxiety that are in various stages of benzodiazepine
dependence to provide peer support through the process.
Changing a culture is time and energy intensive. Therefore, the staff need the support of
the agency to allow these prescribers and staff to take the time needed to educate clients on the
benefits of eliminating these agents and to provide additional tools and resources such as
extended time with prescribers and more opportunities for individual and group therapies to
support clients as they learn to manage their anxiety without the use of benzodiazepines. On
possible solution to this may be the use of two-step appointments wherein the patient’s
appointment with the therapist would precede the prescriber appointment. This would afford the
patient the time and opportunity to work with a clinician on individual CBT or enable the patient
time with the clinician to engage with a web-based CBT program and reinforce skills for selfuse.
During the time this project was conceived, developed, and implemented, this agency
began to work on a benzodiazepine cessation policy and procedure. The project coordinator was
consulted periodically, regarding the progress and outcome of this project. The medical director
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and assistant medical director consulted with the project coordinator throughout that planning
process. On July 1, 2016, the agency adopted a policy that it would become benzodiazepine free
and would begin tapering all benzodiazepines within the year. The policy also requires that no
new prescriptions for benzodiazepines will be started by its prescribers after July 1, 2016. The
implementation of this policy, to date, appears to be going smoothly with minimal disruption to
clients’’ overall anxiety levels.

Required Approvals
Approvals were obtained from the Institutional Review Boards (IRB) of both Bellarmine
University and Seven Counties Services before this pilot project was implemented. The
Bellarmine University IRB is on file in the office of the Department Chair for the Doctorate in
Nursing Practice Program, Dr. Sherrill Cronin. The IRB approval letter can be found in
Appendix F.
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Living Life to the Fullest Web-site

42

REDUCING BENZODIAZEPINE USE IN TREATING ANXIETY
Appendix C
Project Demographics Master Data Collection Tool-Participants
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Project Demographics Master Data Collection Tool- Non-participants
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Appendix E
Aggregate Data- Participants
Participant Beginning
dose
benzo

Participants Change in
score =/-

Ending dose
benzo

% decreased GAD at
beginning of

project

In thx at
beginning of
project?

In thx at
end of
project?

Change in
frequency of
sessions?

Ranking of
Score per
GAD

GAD at end
of project

Ranking of
Score per
GAD

+/-+no
change
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